Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Treating to target is becoming the standard of care in many medical specialities, including rheumatology. The Tight Control of Psoriatic Arthritis (TICOPA) trial has recently provided evidence of the benefit of treating to target in psoriatic arthritis (PsA), and the revised European League Against Rheumatism (EULAR) recommendations on the management of PsA suggest this approach. However, the question of the optimal measure to use and the practicalities of incorporating this into routine clinical practice remain problematic.

Original publication

DOI

10.1136/annrheumdis-2015-208617

Type

Journal article

Journal

Ann rheum dis

Publication Date

04/2016

Volume

75

Pages

640 - 643

Keywords

Outcomes research, Psoriatic Arthritis, Treatment, Antirheumatic Agents, Arthritis, Psoriatic, Humans, Outcome Assessment (Health Care), Patient Care Planning, Practice Guidelines as Topic